Kestra Medical Technologies (NASDAQ:KMTS) Insider Traci Umberger Sells 5,887 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 5,887 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $22.74, for a total value of $133,870.38. Following the sale, the insider owned 215,747 shares of the company’s stock, valued at approximately $4,906,086.78. This represents a 2.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 5.1%

Shares of KMTS stock opened at $23.99 on Tuesday. The stock’s fifty day moving average price is $22.62 and its 200 day moving average price is $22.48. Kestra Medical Technologies, Ltd. has a 1-year low of $14.10 and a 1-year high of $30.00. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -9.91 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. On average, research analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on KMTS shares. The Goldman Sachs Group lowered their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. BTIG Research boosted their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $27.83.

More Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

Institutional Trading of Kestra Medical Technologies

Several institutional investors and hedge funds have recently bought and sold shares of KMTS. Price T Rowe Associates Inc. MD boosted its holdings in shares of Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after acquiring an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. raised its holdings in shares of Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after purchasing an additional 428,996 shares during the last quarter. Alliancebernstein L.P. lifted its position in Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after purchasing an additional 179,885 shares during the period. Eventide Asset Management LLC boosted its holdings in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after purchasing an additional 65,288 shares during the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after purchasing an additional 612,343 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.